CXCR4阳性Lewis肺癌细胞耐药实验研究  

Chemoresistance of CXCR4 positive cells in Lewis lung carcinoma cell line

作　　者：辇伟奇[1] 敖绪军[2] 陈芳琳[1] 陈正堂[1] 

机构地区：[1]第三军医大学新桥医院全军肿瘤研究所,重庆400037 [2]解放军第532医院普通外科,安徽黄山245041

出　　处：《局解手术学杂志》2009年第6期371-373,376,共4页Journal of Regional Anatomy and Operative Surgery

基　　金：国家高技术研究发展计划"863"项目(2007AA02Z129);国家自然科学基金项目(30901790);重庆市自然科学基金项目(2008BB5117)

摘　　要：目的研究CXCR4阳性Lewis肺癌细胞(Lewis lung carcinoma,LLC)原发性耐药机制。方法激光共聚焦检测小鼠移植瘤组织内CXCR4阳性LLC;以CXCR4作为磁珠分选细胞的表面标志,应用CCK-8法检测CXCR4阳性和阴性LLC对顺铂的敏感性,RT-PCR检测两者ABCG2、IGF1RmRNA表达情况。结果小鼠移植瘤组织内散在分布胞膜呈红色荧光的CXCR4阳性LLC;CXCR4阳性与阴性LLC比较,具有更强的增顺铂抗拒性(P<0.05);CXCR4阳性LLC的ABCG2mRNA表达(0.5240±0.0078)明显高于CXCR4阴性LLC(0.3870±0.0066),相差显著(P<0.01);CXCR4阳性LLC的IGF1RmRNA表达(0.4209±0.0074)明显高于CXCR4阴性LLC(0.1848±0.0066),相差显著(P<0.01)。结论Lewis肺癌细胞中的CXCR4阳性亚群具有更强上调ABCG2、IGF1R表达的能力,具有顺铂抗拒性。Objective To explore the chemoresistance mechanism of the CXCR4 positive cells in Lewis lung carcinoma cell line（LLC）. Methods CXCR4-positive LLC were observed by laser scanning confocal microscope （LSCM）. Isolated by magnetic cell sorting,CXCR4-positive and CXCR4-negative LLC were planted in 96-well plates,and cisplatin was added in a concentration gradient. CCK-8 cell viability assay was used to determine theirs chemotherapy sensitivity to cisplatin.RT-PCR was performed to analyze ABCG2 and IGF1R mRNA express in CXCR4-positive and CXCR4-negative populations. Results Red immunofluorescent staining cells scattered in LLC growing tumor tissue. The chemotherapy sensitivity to cisplatin of CXCR4-positive LLC were lower than of CXCR4-negative LLC（ P 〈0.05）.The expression of ABCG2 mRNA in CXCR4-positive LLC（0.5240±0.0078） was higher than that in CXCR4-negative LLC （0.3870±0.0066）. The expression of IGF1R mRNA in CXCR4-positive LLC（0.4209 ±0.0074）was higher than that in CXCR4-negative LLC（ 0.1848 ± 0.0066 ）. Conclusion CXCR4-positive LLC exhibite higher resistance to chemotherapeutic drugs than CXCR4-negative LLC. The drug-resistance machanism may be relate to the over expression of ABCG2 and IGF1R.

关 键 词：LEWIS肺癌细胞 CXCR4 耐药机制 

分 类 号：R734[医药卫生—肿瘤]